

## Small Molecules

### Rucaparib

Poly ADP ribose polymerase (PARP) inhibitor

Catalog #100-1168

25 mg



Scientists Helping Scientists™ | [WWW.STEMCELL.COM](http://WWW.STEMCELL.COM)

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


[INFO@STEMCELL.COM](mailto:INFO@STEMCELL.COM) • [TECHSUPPORT@STEMCELL.COM](mailto:TECHSUPPORT@STEMCELL.COM)

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

## Product Description

Rucaparib is a cell-permeable poly ADP ribose polymerase (PARP) inhibitor (PARP1  $K_i < 5$  nM; Thomas et al.) which also inhibits PARP2, 3, 4, 12, 15, and 16, as well as tankyrase 1 and 2 (Musella et al.). Rucaparib is a selective inhibitor of PARP in human cancer cells with BRCA-1 or BRCA-2 mutations (Musella et al.). DNA breaks activate PARP, which promotes repair of DNA damage through the relaxation of chromatin and recruitment of other repair proteins. Rucaparib inhibits this activity, which leads to DNA damage and cancer cell death (Javle & Curtin).

Alternative Names:	AG014699; PF01367338
CAS Number:	283173-50-2
Chemical Formula:	$C_{19}H_{18}FN_3O$
Molecular Weight:	323.4 g/mol
Purity:	≥ 98%
Chemical Name:	8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one
Structure:	



## Properties

Physical Appearance:	A yellow powder
Storage:	Product stable at -20°C as supplied. As a precaution, STEMCELL recommends storing all small molecules away from direct light. For long-term storage, store with a desiccant. Stable as supplied for 12 months from date of receipt.
Solubility:	<ul style="list-style-type: none"><li>• DMSO ≤ 75 mM</li></ul> For example, to prepare a 10 mM stock solution in DMSO, resuspend 10 mg in 3.09 mL of DMSO. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported; however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

## Published Applications

### CANCER RESEARCH

- Antagonizes multidrug resistance (MDR) in doxorubicin and paclitaxel resistance cervical cancer cell lines by binding to the active site of ATP-binding cassette (ABC) transporters (Chen et al.).
- Cytotoxic to human cell lines with mutated BRCA1/2 (MDA-MB-436, HCC1937, and CAPAN-1) and to UACC3199 cells with epigenetically silenced BRCA1, but not to cell lines without BRCA1/2 mutations (MCF7, MDA-MB-231, HCC1937-BRCA1, and OSEC-2), or heterozygous for BRCA2 mutation (OSEC-1) (Drew et al.).
- Reduces growth of mouse xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 (Drew et al.).
- Concentration-dependent antiproliferative effects in many ovarian cancer cell lines with and without BRCA1/2 mutations (Ihnen et al.).

## References

Chen Z et al. (2020) Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters. *Gene* 759: 145000.

Drew Y et al. (2011) Therapeutic potential of poly (ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. *JNCI J Natl Cancer Inst* 103(4): 334–46.

Ihnen M et al. (2013) Therapeutic potential of the poly (ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. *Mol Cancer Ther* 12(6): 1002–15.

Javle M & Curtin NJ. (2011) The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. *Ther Adv Med Oncol* 3(6): 257–67.

Musella A et al. (2018) Rucaparib: an emerging parp inhibitor for treatment of recurrent ovarian cancer. *Cancer Treat Rev* 66: 7–14.

Thomas HD et al. (2007) Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. *Mol Cancer Ther* 6(3): 945–56.

## Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, visit [www.stemcell.com/smallmolecules](http://www.stemcell.com/smallmolecules), or contact us at [techsupport@stemcell.com](mailto:techsupport@stemcell.com).

**This product is hazardous. Please refer to the Safety Data Sheet (SDS).**

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2023 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.